1 Healthcare Stock for Long-Term Investors and 2 Facing Challenges
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 27.5% over the past six months, topping the S&P 500 by 16.2 percentage points.
Yahoo15 gün önceSOLV
Are Wall Street Analysts Bullish on Solventum Stock?
Solventum has underperformed the broader market, while analysts remain moderately optimistic about its future prospects.
Yahoo21 gün önceSOLV
Solventum (SOLV) Q2 2026 Earnings Call Transcript
CEO Hanson discusses HIS separation strategy and $2.2B in quarterly sales growth.
Yahoo22 gün önceSOLV
SOLV Q2 Deep Dive: Portfolio Restructuring and ERP Transition Shape Outlook
Healthcare solutions provider Solventum (NYSE:SOLV) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 2.2% year on year to $2.21 billion. Its non-GAAP profit of $2.55 per share was 33.8% above analysts’ consensus estimates.
Yahoo24 gün önceSOLV
Solventum (SOLV) Stock Fair Value Rises After Q2 And HIS Separation Plans
Solventum’s analyst fair value estimate has been revised from US$82.15 to US$93.15, a shift of about 13% in the updated framework. This adjustment aligns with recent analyst commentary that points to Q2 results, the planned Health Information Systems separation, and views on the company’s MedTech focus as reasons to revisit price targets. Read on to see how these factors shape the evolving Solventum narrative and what to watch as new data comes in. Analyst Price Targets don't always capture...
Yahoo26 gün önceSOLV
Solventum Q2 Earnings Call Highlights
Solventum (NYSE:SOLV) reported second-quarter results that exceeded its internal expectations, supported by broad-based segment performance, planned order activity ahead of an ERP cutover and a tariff refund benefit. The company also announced plans to separate its Health Information Systems, or HIS
Yahoo26 gün önceSOLV
Solventum Stock Up as Q2 Earnings & Revenues Beat Estimates
SOLV's Q2 earnings and revenues beat estimates as organic sales increase 9.5%, prompting higher 2026 guidance despite ERP timing benefits.
Yahoo28 gün önceSOLV
UBS Maintains Buy on Solventum, Raises Price Target to $101
UBS analyst Kevin Caliendo maintains Solventum (NYSE:SOLV) with a Buy and raises the price target from $95 to $101.
Benzinga29 gün önceSOLV